TORNA ALL’ELENCO

Long term (48-weeks) effectiveness, safety and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in real-world: The early 2 study in Journal of the Neurological Sciences

2021
ASL Asti

Tipo pubblicazione

Conference Abstract

Autori/Collaboratori (33)Vedi tutti...

Aurilia C
IRCCS San Raffaele, Headache And Pain Unit, Rome, Italy
Cevoli S
IRCCS Istituto delle Scienze Neurologiche, Headache Center, Bologna, Italy
Egeo G
IRCCS San Raffaele, Headache And Pain Unit, Rome, Italy

et alii...

Abstract

Background and aims: To assess the long-term effectiveness, safety and tolerability of erenumab in a real-world migraine population, looking for putative predictors of responsiveness. Methods: In 48-week, multicenter (n = 15) longitudinal cohort real life study, all consecutive adult patients with high-frequency episodic migraine (HFEM) or chronic migraine (CM) received erenumab 70 mg monthly. Change in monthly migraine days (MMD) at weeks 45–48 compared to baseline was the primary efficacy endpoint. Secondary endpoints encompassed change in monthly analgesic intake (MAI), ?50%, ?75%, or 100% response rates, VAS and HIT-6 scores. Results: Of the 242 patients treated with >1 dose, 221 received erenumab for >48 weeks. Patients had >3 prior preventive treatments failures. Most subjects received 140 mg. From baseline to weeks 45–48, erenumab reduced MMD by 4.3 days in HFEM and 12.8 in CM. VAS and HIT-6 were decreased by 1.8 and 12.3 in HFEM, and 3.0 and 13.1 in CM. MAI passed from 11 to 5 in HFEM and from 20 to 6 in CM. >50% responders were 56.1% in HFEM and 75.6% in CM, >75% were 31.6% and 44.5%, and 100% responders 8.8% and 1.2% respectively. Erenumab was safe. Responsiveness predictors were allodynia (p = 0.009) in HFEM and male gender (p = 0.044) and baseline migraine frequency (p = 0.001) in CM. Negative predictors in CM were psychiatric comorbidities (p = 0.023) and prior treatment failures (p = 0.004). Conclusions: Long-term erenumab treatment provides sustained effectiveness, safety and tolerability in HFEM or CM patients with >3 prior preventive treatment failures.

DOI : 10.1016/j.jns.2021.117716

Keywords

analgesic agent; erenumab; adult; allodynia; cohort analysis; comorbidity; conference abstract; controlled study; drug safety; drug therapy; drug tolerability; episodic migraine; female; gender; human; major clinical study; male; multicenter study; pharmacokinetics; prophylaxis; transformed migraine; treatment failure;